AstraZeneca buys DSM's Montreal facility

Guest Contributor
June 18, 2007

AstraZeneca has acquired the mothballed Montreal biologics manufacturing facility from DSM Biologics Inc — the second major investment the UK-based pharmaceutical firm has made in Montreal this year. AstraZeneca will begin re-commissioning the facility immediately and expects to begin full-scale production in 2009. Located adjacent to the National Research Council's Biotechnology Research Institute, it will be used to manufacture antibody drug candidates for clinical trials for the company's global operations. DSM Biologics purchased the facility from BioIntermediair and had ambitious plans for a $450-million expansion (R$, October 7/02). Those plans were abandoned when DSM implemented a new corporate strategy focused on outsourcing of a new manufacturing technology platform in conjunction with Dutch-based Crucell NV. Earlier this year, AstraZeneca announced a $10-million expansion of its pain control research centre in the Saint-Laurent Technoparc — the company's first major R&D facility outside of its home base in Sweden (R$, February 26/07).

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.